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A B S T R A C T
Since metastasis accounts for the majority of cancer-associated deaths, studies on the mechanisms of metastasis
are needed to establish innovative strategies for cancer treatment. We previously reported that melanoma cell
adhesion molecule (MCAM) functions as a critical receptor for S100A8/A9, and binding of S100A8/A9 to MCAM
results in the migration of melanoma cells to lung tissue. However, the critical role of MCAM in the original
melanoma skin lesion is still not clear. In this study, we aimed to determine the importance of the S100A8/A9-
MCAM axis in melanoma dissemination in a skin lesion as a critical early step for metastasis. Mechanistic studies
revealed the downstream signaling of MCAM that signaled the induction of metastasis. S100A8/A9-MCAM
binding activates mitogen-activated protein kinase kinase kinase 8 (MAP3K8), also termed TPL2, leading to
strong activation of the transcription factor ETV4 and subsequent induction of matrix metalloproteinase-25
(MMP25), and finally to induction of melanoma lung tropic metastasis. Collectively, our results demonstrate a
crucial role of the S100A8/A9-MCAM signaling axis in metastatic onset of melanoma cells and indicate that
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strategies targeting the identified pathway may be useful for the establishment of innovative anti-cancer
therapies.
1. Introduction
Melanoma is a life-threatening disease due to its rapid and ag-
gressive dissemination to remote areas (metastasis), which can cause
serious organ dysfunctions [1,2]. A better understanding of the sys-
tematic induction of metastasis at the molecular level is needed to es-
tablish an effective strategy for metastatic cancer therapy.
For some time now, cancer researchers have noticed that certain
organs appear to be favored for metastasis of particular cancers. In
1889, Stephen Paget proposed the “seed and soil” hypothesis to explain
the interesting relationship between cancer cells and their pre-meta-
static organ of preference [3]. However, there is still insufficient mo-
lecular-level evidence to validate this theory.
Much progress has recently been made in the understanding of organ-
specific metastasis. Hiratsuka et al. showed that S100A8/A9, a heterodimer
complex of S100A8 and S100A9 proteins, functions as a strong soil signal in
the pre-metastatic lung; S100A8/A9 attracts seed melanoma cells to the
area in which it is produced through a soil signal sensor, toll-like receptor 4
(TLR4), that is expressed in the cancer region [4]. Like TLR4, the receptor
for advanced glycation endproducts (RAGE) also acts as an S100A8/A9
receptor, and binding of S100A8/A9 to RAGE leads to the migration of
melanoma cells to lung tissue [5]. We have recently reported two other
receptors that are important for melanoma organ-specific metastasis: ex-
tracellular matrix metalloproteinase inducer (EMMPRIN) and melanoma
cell adhesion molecule (MCAM) [6–8]. Interestingly, we found that EMM-
PRIN favors S100A9 and that their binding resulted in the migration of
melanoma cells into the bloodstream and subsequent accumulation in ar-
tificially S100A9-enriched skin tissue in a mouse model [6]. MCAM, which
responds to S100A8/A9, induces lung-specific metastasis of melanoma cells
in which it is expressed [8]. These receptors may therefore coordinately
function in melanoma cells to produce the driving force leading to S100A8/
A9-mediated organ-specific metastasis. It has been shown that EMMPRIN
triggers its own downstream signal onset, which links to NF-κB activation
through the TRAF2 adaptor [7]. However, insufficient progress has been
made in elucidation of the MCAM downstream signals.
The aim of this study was to determine the signal pathway triggered
by MCAM activation upon S100A8/A9 binding. We revealed for the first
time that ETS translocation variant 4 (ETV4), also known as polyoma
enhancer activator 3 (PEA3), which exists downstream of MCAM, is a
key transcription factor (TFs) for inducing melanoma metastasis through
significant induction of matrix metalloproteinase-25 (MMP25). We also
found that mitogen-activated protein kinase kinase kinase 8 (MAP3K8),
termed TPL2, which binds to MCAM, plays a key role in the activation of
ETV4. Finally, our findings revealed that the novel pathway triggered by
MCAM-S100A8/A9 binding enhances dissemination of melanoma in the
original skin lesion and subsequent lung metastasis. These results should
contribute to our understanding of the molecular mechanisms underlying
the complex regulatory maze of cancer metastasis.
2. Materials and methods
2.1. Cell lines and reagents
The following cell lines were used in this study: normal human
melanocytes (NMC; KURABO Lifeline Cell Technology, Osaka, Japan),
normal human keratinocytes (NHK; KURABO Lifeline Cell Technology),
HEK293T (a human embryonic kidney cell line stably expressing the
SV40 large T antigen; RIKEN BioResource Center, Tsukuba, Japan), two
human melanoma cell lines established from the same patient—i.e.,
WM-115 (derived from the primary tumor; ATCC, Rockville, MD) and
WM-266-4 (derived from a metastatic site; ATCC)—and mouse mela-
noma cell line B16-BL6, a highly invasive variant of the mouse mela-
noma B16 cell line (a kind gift from Dr. Isaiah J. Fidler, M.D., Anderson
Cancer Center, Houston, TX).
NMC was maintained in DermaLife® Basal Medium (KURABO
Lifeline Cell Technology) supplemented with a DermaLife® M
LifeFactors Kit (KURABO Lifeline Cell Technology). NHK was main-
tained in HuMedia-KG (KURABO Lifeline Cell Technology) supple-
mented with 10 μg/ml insulin, 0.1 ng/ml hEGF, 0.67 μg/ml hydro-
cortisone hemisuccinate and bovine pituitary extract (BPE) (KURABO
Lifeline Cell Technology). HEK293T, WM-115 and WM-266-4 were
cultivated in D/F medium (Thermo Fisher Scientific, Waltham, MA)
supplemented with 10% FBS (Intergen, Purchase, NY). U0126, a se-
lective inhibitor of ERK1/2, was purchased from Sigma-Aldrich (St.
Louis, MO). All cultures were regularly checked for mycoplasma by
using both a mycoplasma detection kit (Thermo Fisher Scientific) and
Hoechst 33342 staining. Authentication of WM-115, WM-266-4 and
B16-BL6 was verified by short tandem repeat DNA profiling.
2.2. Preparation of recombinant S100A8/A9
Human S100A8/A9 recombinant protein was prepared using the
FreeStyle 293 Expression System (Thermo Fisher Scientific) as previously
reported [8]. Briefly, after transfection of the 293-F cells (1×106 cells)
with 150 μg of an expression plasmid carrying both the human S100A8
and S100A9 genes using 293-Fectin-transfection reagent (Thermo Fisher
Scientific), the cells were cultivated in a 500-mL flask filled with 150ml
of medium using an orbital shaker (125 rpm) at 37 °C in the presence of
8% CO2 for 4 days. The culture medium, which included the S100A8/A9
secreted from the cultured cells, was collected and concentrated by an
Amicon Ultra centrifugal filter unit (Merck Millipore, Billerica, MA).
Subsequently, S100A8/A9 protein in the concentrated medium was
captured by Talon® Metal affinity resin (Takara Bio, Shiga, Japan) and
eluted with 150mM imidazole. The solution including S100A8/A9 re-
combinant protein was exchanged for PBS using a Sephadex G25M
column chromatograph (GE Healthcare, Piscataway, NJ) and sterilized
with 0.22-μm Millex-GV syringe filters (Merck Millipore).
2.3. Plasmid constructs
To induce efficient expression of the transgenes in a temporal
manner, we inserted the cDNAs of interest into pIDT-SMART (C-TSC)
vector [9]. The prepared cDNAs were as follows: human cDNAs encoding
MCAM, MCAM dn (deletion of cytoplasmic tail: 584–646 aa), ETS family
genes (ETV1, ETV4, ETV5, ELK, EHF, ERG, ELF, FEV and SPDEF), ETV4
dn (deletion of C-terminal DNA binding domain: 342–484 aa), MAPK
cascade upstream kinases (NAK, NIK, TAK1, DLK, TPL2, ASK1, SPRK,
MLK1, MEKK3, LZK, MLK4, ARAF, BRAF, CRAF, MOS and MKK5) and a
kinase dead type of TPL2 [TPL2 mut (KD); 167K replaced by M]. MCAM
and MCAM dn were designed for expression as C-terminal 3xHA-6His-
tagged forms. ETS family genes, ETV4 dn, MAPK cascade upstream ki-
nases and TPL2 mut (KD) were designed for expression as C-terminal
Myc-6His-tagged forms. Cells were transiently transfected with the
plasmid vectors using FuGENE-HD (Promega, Madison, WI).
To obtain foreign gene-overexpressing clones that show sig-
nificantly high expression levels of the transduced genes in an efficient
and stable manner, we improved the pIDT-SMART (C-TSC) to a stable
expression version, resulting in two types of improved plasmids, named
pSAKA-1B [7] and pSAKA-4B [10]. The expression vector pSAKA-1B
can be used for expression in Chinese hamster ovary (CHO) cells at a
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very high level, while pSAKA-4B is adapted to express significantly high
levels of the target genes in a wide range of mammalian cell lines from
different species in a constant manner. We therefore used pSAKA-4B to
establish B16-BL6-based clones in this study. MCAM (wt)-3xHA-6His
and ETV4 (wt and dn)-3xMyc-6His were inserted into pSAKA-4B.
Human MMP25, which was designed to express either of the N-terminal
3xHA-tagged forms (see Supplementary Fig. S7A), was also inserted
into the same vector. A series of clones (see Supplementary Figs. S3 and
S4, S7B-S7I) were established by a convenient electroporation gene
delivery method and subsequent selection with puromycin at 20 μg/ml.
2.4. Quantitative real-time PCR analysis
The prepared mRNAs (500 ng) from cultured cells (1×106 cells) were
reversed to cDNAs by SuperScriptTM II (Thermo Fisher Scientific). The
cDNA solutions were diluted 1:10 in MilliQ water and used for the next
PCR reaction. Real-time RT-PCR was performed using a LightCycler rapid
thermal cycler system (ABI 7900HT; Applied Biosystems, Foster City, CA)
with LightCycler 480 SYBR Green I Master Mix (Roche Diagnostics,
Indianapolis, IN). The forward and reverse primer pairs used (5′ to 3’) are
listed in Table S4. TBP expression was used as a reliable calibration control.
2.5. SiRNA and decoy DNA
Human MCAM siRNAs (#1 ID No. s8571, #2 ID No. s8572), mouse
Mmp25 siRNAs (#1 ID No. s109154, #2 ID No. s109155, #2 ID No.
s109156) and control siRNA (Silencer Negative control siRNA) were
purchased from Thermo Fisher Scientific. Decoy DNAs for four tran-
scription factors—ETS, GATA, NFI and PPAR—were prepared by hy-
bridizing primer pairs corresponding to each TF. The primer sequences
are shown in Supplementary Table S2 siRNAs (50 nM) and decoy DNAs
(1 μM) were transfected into cells (3× 105 cells) using Lipofectamin
RNAiMAX reagent (Thermo Fisher Scientific).
2.6. Co-immunoprecipitation and western blotting
Co-immunoprecipitation and Western blotting are described in the
Supplementary Materials and Methods.
Fig. 1. MCAM stimulates cellular migration
and growth in response to S100A8/A9 in
melanoma cells. A, Quantitative real-time
PCR analysis was carried out in WM-115
and WM-266-4 cells for the MCAM gene.
The relative expression level in each sample
after calibration with the TBP value is
shown. B, Migration of WM-115 cells
transfected with the indicated gene (GFP as
a control or MCAM) was assessed by the
Boyden chamber method. The transfected
cells were placed in the top chamber, and
purified recombinant S100A8/A9
(1000 ng/ml) was added (+) or not added
(−) to the bottom well. Quantified results
are shown in the upper panel and re-
presentative images of migrating cells are
shown in the bottom panel. C, WM-266-
4 cells were transfected with either siMCAM
or a negative control scrambled siCont, and
cellular MCAM protein in the treated cells
was detected by WB. D, siRNA-treated WM-
266-4 cells were assessed for their migra-
tion abilities in response to extracellular
S100A8/A9 (1000 ng/ml) by the same
method described in (B). E, siRNA-treated
WM-266-4 cells were also evaluated for
their growth conditions by MTS assay in the
presence (+) or absence (−) of S100A8/A9
(1000 ng/ml) in the media. Data are
means ± SD; N.S: not significant;
*P < 0.05, **P < 0.01 and
***P < 0.001.
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2.7. Immunocytochemistry and immunohistochemistry
Immunocytochemistry and immunohistochemistry are described in
the Supplementary Materials and Methods.
2.8. Protein/DNA array and electrophoretic mobility shift assay (EMSA)
Screening of activated TFs through MCAM overexpression in
HEK293T cells (1× 106 cells) was performed by using a protein/DNA
array I (Thermo Fisher Scientific) according to the manufacturer's in-
structions.
Nuclear extracts from WM-266-4 cells (1× 106 cells) were prepared
according to the manufacturer's instructions using NE-PER Nuclear and
Cytoplasmic Extraction Reagents (Thermo Fisher Scientific), and EMSA
was performed using a LightShift Chemiluminescent EMSA kit (Thermo
Fisher Scientific). A 5′-biotin-labeled double-stranded probe (forward:
5′-agtacCGGAAGTaca-3’; reverse: 3′-tgtACTTCCGgtact-5′) was pur-
chased from Sigma-Aldrich. Rabbit anti-human PEA3/ETV4 antibody
(Novus, Littleton, CO) was used for super shift analysis. After the re-
actions, all samples were fractionated by 7% PAGE and blotted onto a
Biodyne B nylon membrane (Pall, Tokyo).
Fig. 2. Identification of ETV4, which plays
a pivotal role in S100A8/A9-MCAM-medi-
ated upregulation of cellular motility. A, A
protein/DNA array was used to detect acti-
vated transcription factors by MCAM over-
expression in HEK293T cells. B, WM-266-
4 cells were transfected with the indicated
decoy DNA fragments (0.1 μM) and then
subjected to the Boyden chamber-based
migration assay. C, D, WM-115 cells were
temporally overexpressed with the in-
dicated gene expression plasmids and then
plated on the top surface of non-sealed in-
serts (C) or Matrigel-sealed inserts (D). The
migrating cells that passed through the
filter membranes in the top inserts were
evaluated. E, WM-115 cells were co-trans-
fected with MCAM + GFP, MCAM + ETV4
wt or MCAM + ETV4 dn, and the trans-
fectants were assessed for their migration
abilities. F, WM-266-4 cells with over-
expression of the indicated genes were as-
sessed for their migration abilities in the
presence (+) or absence (−) of S100A8/A9
(1000 ng/ml) in the bottom media. Data are
means ± SD; N.S: not significant;
*P < 0.05, **P < 0.01 and
***P < 0.001.
Y. Chen, et al. Cancer Letters 452 (2019) 178–190
181
Fig. 3. An electrophoretic mobility shift assay (EMSA) was performed in WM-266-4 nuclear extracts with a biotin-conjugated double stranded oligonucleotide probe
that is specific for binding with ETS family proteins. A, A consensus ETV4-responsive sequence was used as a probe (left panel). The sequence was designed on the
basis of a publicly available database (JASPAR matrix model:http://jaspar.genereg.net/cgi-bin/jaspar_db.pl?rm=browse&db=core&tax_group=vertebrates). WM-
266-4 cells were treated with S100A8/A9 (1000 ng/ml) at regular time intervals. ETV4-specific binding was confirmed by the appearance of a super-shift band using
ETV4 IgG (right panel). B, ETV4 activation was evaluated after transfection of WM-266-4 cells with either MCAM DN plasmid or MCAM siRNA (siMCAM #1) and
subsequent treatment of the transfectants with S100A8/A9 (1000 ng/ml) for six hours. C, Expression and localization of MCAM and ETV4 in clinical melanoma
samples. Paraffin-embedded human melanoma sections were co-stained with MCAM antibody (green) and ETV4 antibody (red). Representative images of MCAM and
ETV4 staining (Scale, 200 μM). . (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)
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2.9. Luciferase-based reporter gene assay
The human MMP25 promoter (3237 bp with SacI and HindIII sites
from the translation start site) was cloned into the luciferase reporter
vector pGL4.11 (Promega), yielding pGL4.11-pMMP25-Luc. Either the
pGL4.11-pMMP25-Luc or pGL4.74 vector encoding Renilla luciferase
regulated under the HSV-TK promoter as an internal control (Promega)
was transfected into HEK293T cells (2× 104 cells) using the transfec-
tion reagent polyethyleneimine Max (Polyscience, Warrington, PA). For
co-transfection, pIDT-SMART (C-TSC)-ETV4-wt and –ETV4-dn were
used for the MMP25 promoter. After 48 h, the transfected cells were
washed with PBS and promoter activities were measured using the
Dual-Luciferase Reporter Assay System (Promega).
2.10. Cell proliferation assay
Cells (5× 103 cells/well) were seeded in 96-well plates. Cell pro-
liferation was evaluated by using a Cell-Titer-Glo™ Luminescent Cell
Viability assay kit (Promega) according to the manufacturer's instruc-
tions.
2.11. Migration and invasion assays
Migration and invasion assays were performed by the Boyden
chamber method as described in the Supplementary Materials and
Methods.
2.12. Animal experiments
Experimental protocols were approved by the Animal Experiment
Committee of Okayama University (approval No. OKU-2014011). All
mouse procedures and euthanasia, including cell transplantations, were
done painlessly or under inhalation anaesthesia with isoflurane gas
according to the strict guidelines of the Experimental Animal
Committee of Okayama University. To examine tumor metastasis in
vivo, B16-BL6-originated clones were used in animal experiments. The
established clones (1× 105 cells) were injected into the tail veins of
immunocompetent Balb/c mice at the age of 6 weeks (Charles River
Laboratories, Yokohama, Japan). Three weeks later, metastasized
melanoma distributed throughout the lung was observed by LaTheta® X-
ray computed tomography (CT-scan; Hitachi-Aloka Medical, Tokyo)
and then the lung metastasis was assessed by counting the formed
melanoma foci after sacrificing the tumor-bearing mice.
2.13. Statistical analysis
Data shown are the means ± SD calculated using at least three
independent experiments. Significant differences between the mean
values of each group were determined by Student's t-test.
3. Results
3.1. MCAM stimulates cellular migration and growth in response to
S100A8/A9 in melanoma cells
To examine the role of MCAM in melanoma in response to S100A8/
A9, we first used two human melanoma cell lines, WM-115 and WM-
266-4, obtained from the same patient. The WM-115 cell line was from
the primary tumor in the skin and the WM-266-4 cell line was estab-
lished from a metastasized lymph node [11]. We found that the MCAM
expression level was about two-fold higher in metastatic WM-266-4
cells than in non-metastatic WM-115 cells (Fig. 1A). When foreign
MCAM was overexpressed in WM-115 cells, the migration ability in
response to S100A8/A9 stimulation was upregulated (Fig. 1B). Intrinsic
MCAM in WM-266-4 cells was downregulated by specific siRNAs
(Fig. 1C) and its effect on cellular motility was evaluated. By this
approach, we found that suppression of MCAM expression eliminates
not only the innate power of migration but also its enhancement by
S100A8/A9 stimulation (Fig. 1D). The S100A8/A9-mediated enhance-
ment of growth was also diminished by the reduction of MCAM in WM-
266-4 cells (Fig. 1E). These in vitro data (Fig. 1) together with previous
imaging of S100A8/A9 in a melanoma skin lesion suggest that extra-
cellular S100A8/A9 from keratinocytes plays a critical role in mela-
noma progression, including growth and spread at the primary tumor
site, through melanoma cell surface MCAM. In addition, melanoma
progression might be greatly affected by the MCAM expression level.
3.2. Identification of ETV4, which plays a pivotal role in S100A8/A9-
MCAM-mediated upregulation of cellular motility
We then tried to investigate the S100A8/A9 binding-activated,
MCAM downstream signal that induces the metastatic signaling cascade
in melanoma. The first screening of TFs provided several candidates
that were activated by MCAM overexpression in HEK293T cells (Fig. 2A
and Supplementary Table S1). With respect to the several parameters
examined—namely, higher induction, novelty, and links to cancer
progression—we identified four TFs that met all the criteria, ETS,
GATA, NFI and PPAR, from which we attempted to select a single TF
that was very highly associated with S100A8/A9-MCAM-mediated up-
regulation of cellular motility. By means of a second screening using
DNA decoys (Supplementary Table S2), i.e., synthetic short DNA cis-
elements for TF binding, which compete with intranuclear DNA and
reduce the function of TFs, we found that only the ETS DNA decoy
attenuated the migration capacity of WM-266-4 cells (Fig. 2B). It has
long been recognized that some ETS family members act as oncogenic
proteins [12-15]. We therefore carried out expression profiling of ETS
family members in melanoma cell lines (Supplementary Fig. S1). From
our data, we selected ETS genes that were significantly more highly
expressed in melanoma cells than in NMC across all or only some of the
melanoma cell lines examined. The selected genes were ETV1, ETV4,
ETV5, ELK, EHF, ERG, ELF, FEV and SPDEF. This led us to reexamine
the cellular disseminative activity for the selected genes. Fig. 2 (C and
D) shows that three genes, ETV1, ETV4 and ETV5, have the ability to
significantly enhance both the migration and invasion of WM-115 cells
even with no S100A8/A9 stimulation. To identify the gene that con-
tributes most to melanoma progression, we constructed dominant ne-
gative (dn) forms of the gene with loss of DNA binding capacity. After
transfection of the constructs (ETV1 dn, ETV4 dn and ETV5 dn ex-
pression vectors), we found that the greatest reduction in innate mi-
gration ability was for ETV4 dn-overexpressed WM-266-4 cells. In ac-
cordance with this, S100A8/A9 responsiveness was also diminished
(Supplementary Fig. S2). These results indicated that ETV4 plays a
crucial role in melanoma progression through the S100A8/A9-MCAM
signaling axis, and they were further confirmed in a subsequent assay in
which overexpression of the ETV4 wt remarkably enhanced MCAM-
mediated migration, while ETV4 dn inhibited the function of MCAM in
WM-115 cells (Fig. 2E). Furthermore, in WM-266-4 cells, ETV4 dn led
to a marked reduction of both innate migration activity and the activity
induced by S100A8/A9 (Fig. 2F).
We next examined whether activation of intrinsic ETV4 actually
occurs in response to S100A8/A9 stimulation in WM-266-4 cells. As
shown in Fig. 3A, we confirmed that the DNA binding activity of ETV4
was greatly increased in a time-dependent manner. In turn, the
S100A8/A9-mediated activation of ETV4 was suppressed by either
MCAM dn overexpression or MCAM siRNA transduction (Fig. 3B), in-
dicating that ETV4 activation is largely regulated by the S100A8/A9-
MCAM signaling axis in melanoma cells.
To confirm that MCAM-positive melanoma expresses ETV4 under
physiological conditions, we compared the results of IHC staining for
MCAM and ETV4 in clinical samples of skin malignant melanoma with
those in normal skin tissue. Strong nuclear staining of ETV4 was par-
tially observed in MCAM-positive melanoma in all cases examined
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(Fig. 3C), suggesting the presence of a highly aggressive population
(MCAM + ETV4 double-positive) throughout the entire melanoma
mass.
3.3. TPL2 is a critical activator of ETV4 in the S100A8/A9-MCAM
signaling cascade
Constitutively active mutation of the BRAF gene is a critical event in
melanomagenesis and subsequent malignant progression that occurs in
50%–70% of all melanomas [16–18]. BRAF belongs to the mitogen-
activated protein kinase kinase kinase (MAP3K) family. We therefore
considered that MAP3Ks including BRAF might greatly contribute to
the S100A8/A9-MCAM-ETV4 pathway we newly identified. To in-
vestigate this possibility, we examined the potential interactions
between MCAM and MAPKs. Our candidate screening method for pro-
tein-protein interactions provided novel partners of MCAM for its
downstream signaling, i.e., four MAP3Ks (DLK, TPL2, ASK1 and MLK1)
and one MAP2K (MKK5) (Fig. 4A). Among these, TPL2 alone possessed
a high ability to induce upregulation of cellular motility in WM-115
cells (Fig. 4B). Moreover, TPL2 significantly enhanced ETV4-mediated
migration, and this enhancement was not observed when ETV4 dn was
overexpressed in WM-115 cells (Fig. 4C). To confirm the importance of
TPL2, we constructed an established kinase-dead mutant of TPL2, TPL2
mut (KD), and assessed its effect on the migration of MCAM-highly-
positive WM-266-4 cells. Although the TPL2 wt noticeably increased
the innate activity of migration and S100A8/A9 stimulation further
enhanced the activity, TPL2 mut (KD) showed almost the same level of
migration activity as the control GFP with or without S100A8/A9
Fig. 4. TPL2 is a critical activator of ETV4
in the S100A8/A9-MCAM signaling cas-
cade. A, HEK293T cells were co-transfected
with HA-tagged MCAM and Myc-tagged
upstream kinases: NAK (NF-κB-Activating
Kinase: TBK1), NIK (NF-κB-Inducing Kinase:
MAP3K14), TAK1 (TGF-β-Activated Kinase
1: MAP3K7), DLK (Dual Leucine Zipper-
Bearing Kinase: MAP3K12), TPL2 (Tumor
Progression Locus 2: MAP3K8), ASK1
(Apoptosis Signal-Regulating Kinase 1:
MAP3K5), SPRK (Src-Homology 3 Domain-
Containing Proline-Rich Kinase: MAP3K11),
MLK1 (Mixed Lineage Kinase 1: MAP3K9),
MEKK3 (MAPK/ERK Kinase Kinase 3:
MAP3K3), LZK (Leucine Zipper-Bearing
Kinase: MAP3K13), MLK4 (Mixed Lineage
Kinase 4: MAP3K21), ARAF (A-Raf Proto-
Oncogene, Serine/Threonine Kinase:
ARAF), BRAF (B-Raf Proto-Oncogene,
Serine/Threonine Kinase: BRAF), CRAF (C-
Raf Proto-Oncogene, Serine/Threonine
Kinase: RAF1), MOS (MOS Proto-Oncogene,
Serine/Threonine Kinase: MOS), and MKK5
(MAP Kinase Kinase 5: MAP2K5). After im-
munoprecipitation of the expressed MCAM
with HA antibody-conjugated beads, inter-
acting kinases were detected by the Myc
antibody. Asterisks show the candidates
that interacted with MCAM. B, Five candi-
date kinases as indicated were transfected
into WM-115 cells and their effects on mi-
gration were assessed. C, WM-115 cells
were co-transfected with TPL2 + GFP,
TPL2 + ETV4 wt or TPL2 + ETV4 dn, and
the transfectants were assessed for their
migration abilities. D, WM-266-4 cells with
overexpression of GFP, TPL2 wt or a kinase
dead type (K167 M) of TPL2 [TPL2 mut
(KD)] were assessed for their migration
abilities in the presence (+) or absence (−)
of S100A8/A9 (1000 ng/ml) in the bottom
media. E, WB analysis of the phosphoryla-
tion of effector kinases including ERK1/2,
SAPK/JNK (JNK), p38, and AKT was carried
out by using HEK293T cell extracts with
transfection of GFP, DLK, TPL2, ASK1,
MLK1 or MKK5. F, Migration evaluation
was performed in WM-266-4 cells by the
same method described in (D) except for the
presence (+) or absence (−) of an ERK1/2
selective inhibitor, U0126 (20 μM), in the
culture media. Data are means ± SD; N.S:
not significant; *P < 0.05, **P < 0.01
and ***P < 0.001.
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treatment (Fig. 4D). The slight responsiveness of S100A8/A9 in the case
of TPL2 mut (KD) was probably due to endogenous TPL2 in WM-266-4
cells. It has been reported that ETV4 activation is positively regulated
by ERK1/2 effector kinase [19–21], and we further investigated whe-
ther TPL2 can result in activation-linked phosphorylation of ERK1/2. As
shown in Fig. 4E, we found that TPL2 significantly induced ERK1/2
phosphorylation. When we treated WM-266-4 cells with a selective
ERK1/2 inhibitor, U0126, the TPL2-induced marked elevation of mi-
gration was reduced to the level in non-treated control GFP cells, and
ETV4 overexpression effectively impaired the U0126-induced reduction
of migration (Fig. 4F). Taken together, these results strongly suggest
that TPL2 plays a crucial role in ETV4 activation through ERK1/2
phosphorylation in the region downstream of cell surface MCAM in
response to extracellular S100A8/A9 stimulation, which eventually
leads to acquisition of an advanced spreading phenotype in melanoma
cells.
3.4. ETV4 activation through the S100A8/A9-MCAM axis is critical for
melanoma growth and lung metastasis
To clarify the significance of the identified pathway in melanoma in
in vivometastasis processes, we established several stable transformants
(control GFP, MCAM alone, ETV4 wt alone, ETV4 dn alone,
MCAM + ETV4 wt, MCAM + ETV4 dn) from mouse melanoma B16-
Fig. 5. ETV4 activation through the
S100A8/A9-MCAM axis is critical for
melanoma growth and lung metastasis.
B16-BL6 cell-based stable transfor-
mants with stable overexpression of
foreign genes, GFP alone as a control,
MCAM alone, ETV4 wt alone, ETV4 dn
alone, MCAM + ETV4 wt and
MCAM + ETV4 dn were established
(see Materials and Methods;
Supplementary Figs. S3 and S4). A re-
presentative clone in each group was
selected and examined for the growth
and metastasis in both in vitro and in
vivo experimental settings. A, Cellular
migration (left) and growth (right)
were assessed in the representative
clones by the Boyden chamber method
and MTS assay, respectively. B, Each
representative clone (1× 105 cells)
was injected into mice through the tail
vein. Three weeks later, lung metastatic
nodules were quantified (top). The lung
tumor nodules were observed macro-
scopically (bottom, CT scan images and
resected whole lung pictures) and their
sections were also observed by H&E
staining (C). n = 5. Data are means ±
SD; N.S: not significant; *P < 0.05,
**P < 0.01 and ***P < 0.001.
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Fig. 6. MMP25, a key molecule for the regulation of melanoma motility and invasiveness, is strongly induced by ETV4 activation through the S100A8/A9-MCAM
axis. A, Quantitative real-time PCR analysis was carried out in WM-115 (right) and WM-266-4 (left) for MMP25 genes. Total RNAs were prepared from these genes
with overexpression of an empty vector (EV), ETV4 wt or ETV4 dn. The relative expression level in each sample after calibration with the TBP value is shown. B,
ETV4-mediated promoter activation of MMP25 was evaluated by the luciferase-based reporter gene assay. HEK293T cells were co-transfected with pGL4.14-
pMMP25-Luc and ETV4 wt or ETV4 dn expression plasmids, and the levels of expressed luc activities were measured. C, D, E, B16-BL6 cell-based stable transformants
with stable overexpression of MMP25 alone or MMP25 + ETV4 dn were established (see Materials and Methods; Supplementary Figs. S10 and S11). For the
established clones, cellular migration (C) and invasion (D) were assessed by the Boyden chamber method and evaluation of cell growth (E) was performed by the MTS
assay. Data are means ± SD; N.S: not significant; *P < 0.05, **P < 0.01 and ***P < 0.001. F, Quantitative real-time PCR analysis for the MMP25 gene was
carried out in the indicated cells. The relative expression level in each sample after calibration with the TBP value is shown. G, Double immunofluorescence staining
of MMP25 (red) and either S100A8 (green) or S100A9 (green) was performed in the clinically prepared melanoma sections. (Scale, 50 μm). . (For interpretation of the
references to color in this figure legend, the reader is referred to the Web version of this article.)
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BL6 cells (Supplementary Fig. S3). Random insertions of artificial ex-
pression units into chromosomal DNA sometimes induce unexpected
alterations in the cell character that occur independently of the func-
tions of the overexpressed target molecules. We therefore carefully se-
lected optimal stable clones that represented each function of the ex-
pressed molecules we identified through our previous temporal
expression studies. At first, positive clones were selected according to
the expression levels of the inserted genes (Supplementary Fig. S3), and
then the migration activities of the clones were further checked by an in
vitro trans-chamber assay (Supplementary Fig. S4). Interestingly, the
migration activities of each group showed an almost identical pattern
within each stable transformant. MCAM alone, ETV4 wt alone and
MCAM + ETV4 wt all tended to increase cellular migration among the
clones in each group. GFP stable clones, ETV4 dn alone and
MCAM + ETV4 dn all showed lower activity for cellular migration.
These results reinforced the conclusions of our earlier temporal ex-
pression studies. Finally, we selected one representative clone (control
GFP #3, MCAM alone #6, ETV4 wt alone #5, ETV4 dn alone #1,
MCAM + ETV4 wt #9, MCAM + ETV4 dn #3) in each group and used
them to investigate the metastatic migration abilities in vitro before
performing the in vivo study. The highest activity was observed in clone
MCAM + ETV4 wt #9. MCAM #6 and ETV4 wt alone #5 also showed
positive reactions, but GFP #3, ETV4 dn #1 and MCAM + ETV4 dn #3
all showed reduced activities (Fig. 5A, left). In contrast to the results for
migration (Fig. 5A, left), there were no remarkable differences in
growth among the selected clones except for a slight reduction in
growth of the ETV4 dn #1 clone (Fig. 5A, right). To control for possible
investigator bias based on the clone selection, we examined whether
the cellular behavior observed in the selected B16-BL6 clones matched
the results in a transient expression system. We found that the observed
patterns of migration and growth activities in the selected clones were
indeed very similar to those in the transient expression experiments
using not only B16-BL6 cells (Fig. S5A) but also WM-266-4 cells (Fig.
S5B).
Next, we used these selected clones displaying reliable cellular be-
haviors to examine the migration activities in vivo. We injected the
clones into the tail veins of immunocompetent mice and assessed the
level of lung metastasis (Fig. 5B and C). The number of lung tumor
nodules derived from clone MCAM + ETV4 wt #9 was significantly
larger than that derived from control GFP #3 (Fig. 5B). On the other
hand, the number and size of metastatic tumor nodules in the
MCAM + ETV4 dn #3-injected group were much smaller even with
high expression of foreign MCAM in the injected clone (Supplementary
Fig. S3) than those in the MCAM + ETV4 wt #9-injected group. These
patterns were also reflected in the H&E staining data (Fig. 5C). The
results reveal an unusual role of ETV4 in melanoma lung metastasis in
vivo and show that its function is greatly enhanced by the S100A8/A9
receptor MCAM.
3.5. MMP25, a key molecule for the regulation of melanoma motility and
invasiveness, is strongly induced by ETV4 activation through the S100A8/
A9-MCAM axis
We next investigated how ETV4 triggers melanoma aggressiveness.
Since ETV4 is a transcription factor, it would be expected to regulate
numerous genes. To identify the key ETV4-regulated gene(s) that en-
hance melanoma metastasis, we searched for candidate genes by a
bioinformatics technique. Publicly available data for the PC3 prostate
cancer cell line, LoVo colon cancer cell line and TRANSFAC prediction
database were used for the ETV4-targeted gene promoter. After com-
bining the collected information, 107 overlapped genes appeared
(Supplementary Fig. S6A, Supplementary Table S3). Based on previous
reports and online results of functional analysis of the 107 genes, we
focused on 18 genes as cancer-related genes. However, none of the
genes were significantly associated with the activation of ETV4 in the
case of melanoma cells, since their expressions were not affected by
either ETV4-wt or -dn overexpression in either WM-115 cells
(Supplementary Fig. S6B) or WM-266-4 cells (Supplementary Fig. S6C).
Faced with this unexpected lack of association between ETV4 and the
genes related to melanoma metastasis, we took another approach to
metastasis prediction. Because BRAF plays a critical role in the devel-
opment of melanoma, and TPL2 on the MCAM pathway plays a critical
role in melanoma progression, as described above, we decided to in-
vestigate the relation between the RAF-MAP3K family (ARAF, BRAF,
RAF1) and TPL2 expression [19–21]. Of course, WM-115 and WM-266-
4 cells already harbor constitutively active mutBRAF (V600D) [22,23],
but a significant increase in the gene expression of the kinases may
further enhance melanoma aggressiveness. In addition, we should not
rule out the importance of matrix metalloproteinases (MMPs) in cancer
metastatic progression. We therefore examined whether these genes are
affected by ETV4 at the transcription level in melanoma cells. As shown
in Supplementary Figs. S6D and S6E, although the expression of four
key kinases was not affected by ETV4, we fortuitously found that only
MMP25 was remarkably upregulated by forced expression of ETV4 wt,
but not forced expression of ETV4 dn, in both WM-115 and WM-266-4
cells. This was confirmed by repeating the same experiments (Fig. 6A).
By a reporter gene assay using the MMP25 promoter, we further found
that ETV4 was able to activate the MMP25 promoter with high effi-
ciency (Fig. 6B). This event was also confirmed by the im-
munohistochemistry, i.e., MMP25 staining was highly positive in ma-
lignant melanoma specimens (Supplementary Fig. S7) in which we had
detected pronounced elevation of both MCAM and ETV4 in our earlier
study (Fig. 3C). These staining patterns were not observed in the normal
skin specimens (Supplementary Fig. S7 and Fig. 3C). In addition, in the
in vitro trans-chamber assay, stable transformants expressing a high
level of foreign MMP25 (Supplementary Fig. S8A, schematic of foreign
MMP25 expression; Supplementary Figs. S8B and S8F, expression
check; Supplementary Figs. S8C and S8G, migration check;
Supplementary Figs. S8D and S8H, invasion check; Supplementary Figs.
S8E and S8I, growth check) showed remarkably increased capacity for
motility (Fig. 6C) and invasiveness (Fig. 6D) even in the absence of
extracellular S100A8/A9. These enhanced abilities were not affected by
ETV4 dn overexpression (Fig. 6C and D), except for a negligibly small
reduction in growth activity (Fig. 6E). These cellular events observed in
the selected clones were consistent with the results obtained in the
transient overexpression system (Supplementary Fig. S9A, migration
check; Supplementary Fig. S9B, invasion check; Supplementary Fig.
S9C, growth check). In contrast, cellular migration and invasion ac-
tivities were markedly reduced by the treatment with Mmp25 siRNAs
(siMmp25 #2 and #3) (Supplementary Fig. S10A, expression check;
Supplementary Fig. S10B, migration check; Supplementary Fig. S10C,
invasion check). These results suggest that MMP25 plays a critical role
in melanoma migration and invasion but not in proliferation. In addi-
tion to these in vitro results, we further found that Mmp25 siRNA sig-
nificantly mitigated the metastatic activity of B16-BL6 cells toward the
lung in the in vivo study on mice (Supplementary Fig. S10D). Finally, we
confirmed that overexpression of MMP25 consistently occurred in
human melanoma cell lines but not in normal human melanocytes
(NMC) in culture (Fig. 6F). In addition, the results of clinical melanoma
samples that included normal skin area showed that the melanoma
mass and cells that had disseminated into the neighboring keratinocyte
layer, where S100A8/A9 (green color) was abundant, were strongly
stained with MMP25 (red color) (Fig. 6G).
Collectively, the results suggest an important pathway in melanoma
progression. In a melanoma skin lesion, melanoma-stimulated kerati-
nocytes induce S100A8/A9, which binds to melanoma cell surface
MCAM, resulting in melanoma metastatic progression through a newly
identified pathway, TPL2-ETV4, that is linked to induction of one im-
portant candidate for melanoma dissemination, MMP25, and the
pathway facilitates the migration of melanoma cells to distant lung
tissue (Fig. 7).
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4. Discussion
In this study, we reported a novel role of the S100A8/A9-MCAM
axis in cancer progression in the primary skin lesions of melanoma cells.
We demonstrated that cell surface MCAM functions to activate mela-
noma dissemination upon binding with extracellular S100A8/A9 se-
creted from the surrounding skin keratinocytes in the primary cancer
area. Analysis of the signaling region downstream of MCAM revealed a
novel signaling pathway used by MCAM that plays a crucial role in the
migration and invasion of melanoma cells. In brief, binding of S100A8/
A9 to MCAM leads to the significant activation of MAP3K TPL2, which
in turn induces a much higher level of ETV4 activation, eventually
leading to transactivation of MMP25. We found that induction of a
remarkable level of MMP25 is a cause of the onset of melanoma dis-
semination and subsequent distant lung metastasis.
Due to the biological significance of MCAM in the progression of
various cancers, many studies have been conducted on the roles of this
molecule in cancer, but the relation between the intracellular pathway
of MCAM and the signal transduction in cancer biology remains con-
troversial [8,24,25]. We therefore tried to identify an MAP3K asso-
ciated with MCAM, since MAP3Ks are central kinases for triggering a
series of MAPK cascades that regulate several cellular events [26,27].
Based on the results of our candidate-interaction assay using a series of
MAP3Ks and subsequent cellular motility assay, we identified TPL2 as a
key MAP3K for MCAM signaling in cancer invasiveness. TPL2
(MAP3K8) is also called “Cancer Osaka Thyroid (COT)” because it was
initially cloned as a transforming kinase gene from a human thyroid
carcinoma cell line, suggesting that it has a remarkable function both in
melanoma and other cancers [28]. In melanoma, it is known that on-
cogenic mutation occurs at a high frequency (50%–70%) in another
MAP3K, BRAF [16–18,22], which we found does not bind to MCAM.
Thus, a BRAF inhibitor has been used as a therapeutic agent for mela-
noma [29], but its clinical use is problematic, since the treatment
sometimes causes drug resistance. This may be due to a compensatory
function of TPL2. Johannessen et al. showed that TPL2 causes re-
sistance to a BRAF inhibitor through reactivation of MAPK cascades
[30]. These results strongly suggest that TPL2 derived from MCAM
plays a non-negligible role in melanoma malignancy.
Our results also revealed a critical transcription factor, ETV4,
regulated by the MCAM-TPL2 pathway in melanoma after stimulation
with S100A8/A9. Accumulating evidence indicates that ETV4 activates
melanoma, breast cancer and other types of cancers [31,32]. To de-
termine how ETV4 positively regulates cancer dissemination, we in-
vestigated ETV4 target molecules. It has been reported that ETV4 reg-
ulates many cancer-related genes by its function as a transcription
factor [19,21,33]. However, it seems that the ETV4-based regulation of
genes varies greatly depending on the type of cancer. Complex post-
translational modifications depending on cell types may govern ETV4
specificity, which can selectively promote cell proliferation, motility
and invasion through cancer progression. In our settings using mela-
noma cells, we found that ETV4 regulates a large increase in MMP25
and that the elevation plays a pivotal role in melanoma dissemination in
vitro.
MMP25 is a unique membrane-anchored matrix metalloproteinase
that is located on the cell surface via a glycosyl-phosphatidyl inositol
(GPI) anchor (Supplementary Fig. S8A) [34]. Increased expression of
MMP25 has been found in several types of invasive cancer cells, in-
cluding glioma, colon and prostate cancer cells [35–37]. In addition,
when colon cancer cells were transplanted subcutaneously in mice,
MMP25 showed a specific distribution at the infiltrative rim of the
cancer nugget, suggesting an important role of MMP25 in dissemination
onset of cancer cells at the interface region in the cancer primary site
[36]. A similar phenomenon was also observed in our melanoma study
(Fig. 6G). Collectively, our results support the idea that MMP25 plays
an unusual role in the onset of melanoma dissemination in skin.
An interesting finding in this study was that keratinocytes present at
the interface of melanoma strongly induced S100A8/A9. Hoshino et al.
reported that various S100 genes are induced simultaneously in normal
fibroblasts and Kupffer cells by stimulation with tumor-derived exo-
somes [38]. Based on their results, we added melanoma exosomes to
the culture of keratinocytes. The keratinocytes showed a remarkable
ability to induce S100A8/A9 (Supplementary Figs. S11A–S11D). Thus,
melanoma-secreted exosomes may play a crucial role in the production
and secretion of S100A8/A9 in surrounding keratinocytes, which in
turn may induce dissemination of melanoma cells. Further advanced
analysis is required to elucidate the molecular mechanism of melanoma
progression in response to the cancer microenvironment.
In conclusion, our study demonstrates a critical role of MCAM in
melanoma at the primary skin lesion, where the MCAM ligand S100A8/
A9 is induced and secreted from melanoma-stimulated keratinocytes.
Downstream signaling analysis showed that MCAM promotes activation
of ETV4 through recruitment of TPL2, which is linked to a marked in-
crease in MMP25. The identified pathway could play a major role in
activation of the spread of melanoma. This novel pathway may be a
potential therapeutic target in melanoma.
Fig. 7. Schematic of melanoma dissemination in skin in response to S100A8/
A9.
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